CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says
Executive Summary
The Center for Drug Evaluation and Research's performance in review applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent
You may also be interested in...
FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
FDA Amendments Act Implementation Faces Delay; Agency To Miss Deadlines
FDA is expected to miss a spate of implementation deadlines for provisions of the FDA Amendments Act as the law approaches its first anniversary